Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

7.0K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
7.0K
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

158
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
158
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

249
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
249
Functions of Thyroid Hormones01:18

Functions of Thyroid Hormones

4.8K
The thyroid hormone (TH) plays a pivotal role in the intricate orchestration of physiological processes, exerting profound effects on development, metabolism, and homeostasis throughout different life stages.
TH is indispensable for the normal development and maturation of the skeletal, muscular, and nervous systems during fetal and childhood growth. It facilitates bone mineral turnover and regulates protein synthesis in developing tissues, contributing significantly to overall growth and...
4.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

516
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thyroid eye disease (Graves' orbitopathy): clinical presentation, epidemiology, pathogenesis, and management.

The lancet. Diabetes & endocrinology·2025
Same author

Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis.

The lancet. Diabetes & endocrinology·2023
Same author

Worldwide Consensus on Thyroid Eye Disease? What Is In a Name?

Thyroid : official journal of the American Thyroid Association·2022
Same author

Hypothyroid Symptoms Throughout Pregnancy Are Predominantly Associated with Thyroxine and Not with Thyrotropin Concentrations.

Thyroid : official journal of the American Thyroid Association·2022
Same author

<i>European Thyroid Journal:</i> Looking Backwards and Forwards.

European thyroid journal·2021
Same author

T4+T3 Combination Therapy: An Unsolved Problem of Increasing Magnitude and Complexity.

Endocrinology and metabolism (Seoul, Korea)·2021
Same journal

Tirzepatide as a multi-organ integrator in metabolic diseases: a review of molecular mechanisms and clinical translation.

Endocrine·2026
Same journal

Effects of a single-dose denosumab on glucose and lipid homeostasis in young infertile men.

Endocrine·2026
Same journal

Ultrasound-guided thermal ablation for papillary thyroid microcarcinoma with calcifications: short-term imaging outcomes.

Endocrine·2026
Same journal

Diabetic gastroparesis: pathophysiology and impact on insulin timing choices.

Endocrine·2026
Same journal

Liquid biopsies for BRAF V600E assessment and monitoring in anaplastic thyroid carcinoma: a real-world study of a tertiary cancer center.

Endocrine·2026
Same journal

Interpreting the TIR 3B nomogram as a rule-in rather than rule-out tool.

Endocrine·2026
See all related articles

Related Experiment Video

Updated: Jan 5, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.8K

T4 + T3 combination therapy: any progress?

Wilmar M Wiersinga1

  • 1Department of Endocrinology & Metabolism, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. w.m.wiersinga@amc.uva.nl.

Endocrine
|October 17, 2019
PubMed
Summary
This summary is machine-generated.

Dissatisfaction with levothyroxine (L-T4) monotherapy persists, with many patients experiencing fatigue and cognitive issues. Combination therapy with liothyronine (T3) may help, but more research is needed.

Keywords:
Combination therapyHypothyroidismT3T4

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

19.1K
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.7K

Related Experiment Videos

Last Updated: Jan 5, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.8K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

19.1K
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.7K

Area of Science:

  • Endocrinology
  • Thyroidology
  • Pharmacology

Background:

  • High dissatisfaction with levothyroxine (L-T4) monotherapy for hypothyroidism persists.
  • Patients on L-T4 often report persistent symptoms like fatigue, weight gain, and cognitive dysfunction.
  • Low serum T3 levels are common in L-T4 treated patients, necessitating TSH-suppressive doses for normalization.

Purpose of the Study:

  • To review the understanding of T4+T3 combination therapy for hypothyroidism 7 years after 2012 guidelines.
  • To investigate the reasons for persistent symptoms in patients treated with L-T4 monotherapy.
  • To assess the current evidence and future directions for combination therapy.

Main Methods:

  • Literature review of studies published between 2012 and 2019 on T4+T3 combination therapy.
  • Analysis of thyroid hormone metabolism and peripheral tissue function during T4 monotherapy.
  • Examination of genetic factors, such as DIO2 polymorphisms, potentially affecting T3 conversion.

Main Results:

  • L-T4 monotherapy is associated with suboptimal T3 levels and variable tissue thyroid status.
  • A normal serum TSH does not guarantee a euthyroid state due to differential T4 metabolism.
  • A specific SNP in DIO2 may contribute to local hypothyroidism in the brain, explaining persistent symptoms.

Conclusions:

  • The 2012 European Thyroid Association (ETA) guidelines for T4+T3 combination therapy remain relevant.
  • Individualized, experimental T4+T3 treatment may be considered for selected patients with persistent symptoms.
  • Well-designed randomized clinical trials are crucial for advancing treatment strategies and understanding the complexities of thyroid hormone therapy.